2) O'Brien E, Sheridan J, O'Malley K : Dippers and non-dippers [letter]. Lancet 2 : 397, 1988
3) Tsien RW, Ellinor PT, Zhang J-F et al : Molecular biology of calcium channels and structural determinants of key functions. J Cardiovasc Pharmacol 27 (suppl A) : S4-S10, 1996
4) TiPS Receptor & Ion Channel Nomenclature Supplement 1998. Trends, Pharmacol Sci 9th ed, pp 79-80, 1998
5) 森島繁, 森泰生, 井本桂二 : 電位依存性カチオンチャネルと神経・筋・心疾患-Ca2+チャネル. 「チャネルとトランスポーター : その働きと病気」岡田泰伸, 清野進編, メジカルビュー社, 東京, 1997, pp 31-41
8) 唐木英明 : Ca2+チャネルの分子生物学. Ca拮抗薬のすべて, 猿田享男, 日和田邦男, 荻原俊男編, 先端医学社, 東京, 1998, pp 360-372
11) Krizanova O, Diebold R, Lory P et al : Molecular aspects and diversity of volatage-dependent calcium channels. Circulation 87 (suppl VII) : VII-44-VII-48, 1993
17) Yoshida A, Oho C, Omori A et al : HPC-1 is associated with synaptotagmin and omegaconotoxin receptor. J Biol Chem 267 : 24925-24928, 1992
18) The HOT Study Group. The hypertension optimal treatment study. Blood Pressure 2 : 62-68, 1993
18) Mintz IM, Venema VJ, Swiderek K et al : P-type calcium channels blocked by the spider toxin omega-Aga-IVA. Nature 355 : 827-829, 1991
20) Zanchetti A : Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group. J Hypertens suppl 12 : S23-S27, 1994
31) Endo M : Calcium release from sarcoplasmic reticulum. Phtsiol Rev 57 : 71-108, 1977
32) Fabiato A : Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 245 : C1-Cl4, 1983
33) Fujii S, Kameyama K, Hosono M et al : Effect of cilnidipine, a novel dihydropyridine Ca2+ channel antagonist, on N-type Ca2+ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 280 : 1184-1191, 1997
36) Varadi G, Lory P, Schultz D et al : Acceleration of activation arld inactivation by the β-subunit of the skeletal Inuscle calciun channel. Nature 352 : 159-162, 1991
37) Pragnell M, De Waard M, Campbell KP et al : Calcium channel β-subunit binds to a conserved motif in the I-II cytoplasmic linker of the α1-subunit. Nature 368 : 67-70, 1994
38) Fleckenstein A : Specific inhibitors and promotors of calcium action in the excitation-contraction of heart Inuscle and their role in the prevention or production of myocardial lesions. In : Calcium and the Heart, ed by Harris P, Opie L, Academic Press, New York, 1971, pp 135-138
41) Hashimoto K, Taira N, Chiba S et al : Cardiohemodynamic effects of BAY a 1040 in the dog. Arzneimittelforschung 22 : 15-21, 1972
42) Hashimoto K, Taira N, Ono H et al : Nifedipine basis of its paharmacological effect. In : lst International nifedipne "Adalat" Symposium, ed by Hashimoto K, kimura E, Kobayashi T, University of Tokyo Press, Tokyo, 1973, pp 11-22
43) Taira N : Effects of diltiazem and other calcium-antagonists on cardiac functions and coronary blood flow as assessed in blood-perfused dog-heart preparations. In : Diltiazem Hakone Symposium, ed by RJ Bing, Excerpta Medica, Amsterdam, 1979, pp 91-105
45) 元村成, 橋本敬太郎 : カルシウム拮抗薬の薬理作用-カルシウムチャンネルの構造と機能-. CLINICAL CALCIUM 7 : 17-25, 1992
47) Nakayama H, Taki M, Striessnig J et al : Identification of 1, 4-dihydropyridine binding regions within the α1 subunit of skeletal muscle Ca2+ channels by photoaffinity labeling with diazipine. Proc Natl Acad Sci USA 88 : 9203-9207, 1991
48) Watanabe T, Kalasz H, Schwartz A et al : Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the α1 subunit of the skeletal muscle L-type calcium channel. FEBS Lett 334 : 261-264, 1993
49) Striessnig J, Glossmann H, Catterall WA : Identification of phenylalkylamine binding region within the α1 subunit of skeletal muscle channels. Proc Natl Acad Sci USA 87 : 9108-9112, 1990
51) Sun J, Triggle DJ : Calcium chalmel antagonists : Cardiovascular selectivity of action. J Pharmacol Exp Ther 274 : 419-426, 1995
55) Bolton TB, Kitamura K, Morel N : Usedependent effects of calcium entry blocking drugs on the electrical and mechanical activities of guinea-pig taenia caeci. Br J Pharmacol 78 : 174P, 1983
56) Sannguinetti MC, Kass RS : Voltage-dependent block of calcium chalmel current in the calf cardiac Purkinje fiber by dihydropyridine calcium achannel antagonists. Circ Res 55 : 336-348, 1984
57) Kazda S, Towart R : Differences in the effects of the calcium alltagonists nimodipine (Bay e 9736) and bencyclan on cerebral and peripheral vascular smooth muscle. Br J Pharmacol 72 : 582P-583P, 1981
61) Nayler WG : カルシウム拮抗薬の命名法, 作用動態, 分類, Calcium Antagonists (日本語版) Vol 5, 平則夫監訳, Churchill Livingstone, Japan, 1992, pp 21-33
68) 大西明弘, 石崎高志 : カルシウム拮抗薬の臨床薬理学的特徴. カルシウム拮抗薬-解明された基礎と臨床への応用-, 矢崎義雄, 遠藤政夫編, 医薬ジャーナル社, 大阪, 1995, pp215-221
69) 石崎高志 : Ca拮抗薬の臨床薬理学, 循環器疾患の薬物療法, 南江堂, 東京, 1992, pp191-207
70) Brockmoeller J, Roots I : Assesslnent of liver metabolic function. Clinical implications. Clin Pharmacokinet 27 : 210-248, 1994
76) O'Connor CM, Belkin RN, Carso PE et al : Effects of amlodipine on mode of death in severe chronic heart failure : the PRAISE trial. Circulation 92 (suppl) : 1-143, 1995
78) Perez-Reyes E, Cribbs LL, Daud A et al : Molecular characterization of aneuronal low-voltage-activated T-type calcium channe1. Nature 391 : 896-900, 1998
79) Cibbs LL, Lee J-H, Yang J-H, Yang J et al : Cloning and characterization of a1H from human heart, a member of the T-type Ca2+ channel gena family. Circ Res 83 : 103-109, 1998
80) 0phoff RA, Terwindt GM, Frants RR : P/Q -type Ca2+ channel defects in migrane, ataxia and epilepsy. Trends Pharmacol Sci 19 : 121-127, 1998
